Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 10;25(14):7580.
doi: 10.3390/ijms25147580.

Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Luis Miguel Juárez-Salcedo  1 , Santosh Nimkar  2 , Ana María Corazón  3 , Samir Dalia  4
Affiliations
Review

Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Luis Miguel Juárez-Salcedo et al. Int J Mol Sci. .

Abstract

Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New molecules have entered the immunotherapy arsenal. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal conjugated antibody, which consists of an anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.

Keywords: antibody–drug conjugate; diffuse large-B-cell lymphoma; immunotherapy; loncastuximab tesirine; refractory/relapse.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Structure of Loncastuximab.
Figure 2
Figure 2
Mechanisms of action of Loncastuximab.
See this image and copyright information in PMC

References

    1. Sehn L.H., Salles G. Diffuse Large B-Cell Lymphoma. N. Engl. J. Med. 2021;384:842–858. doi: 10.1056/NEJMra2027612. - DOI - PMC - PubMed
    1. Coiffier B., Lepage E., Brière J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Gisselbrecht C., Van Den Neste E., Salles G., et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. N. Engl. J. Med. 2002;346:235–242. doi: 10.1056/NEJMoa011795. - DOI - PubMed
    1. Maurer M.J., Ghesquières H., Jais J.-P., Witzig T.E., Haioun C., Thompson C.A., Delarue R., Micallef I.N., Peyrade F., Macon W.R., et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 2014;32:1066–1073. doi: 10.1200/JCO.2013.51.5866. - DOI - PMC - PubMed
    1. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., Lister T.A., Vose J., Grillo-López A., Hagenbeek A., et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J. Clin. Oncol. 1999;17:1244. doi: 10.1200/JCO.1999.17.4.1244. - DOI - PubMed
    1. Crump M., Neelapu S.S., Farooq U., Van Den Neste E., Kuruvilla J., Westin J., Link B.K., Hay A., Cerhan J.R., Zhu L., et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 2017;130:1800–1808. doi: 10.1182/blood-2017-03-769620. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources